Clinical Evaluation of Implantable Insulin Delivery Systems

Abstract

Implantable insulin delivery systems (IIDS) represent the next frontier in Type 1 diabetes management, offering continuous intraperitoneal insulin delivery that mimics physiological portal insulin absorption more closely than subcutaneous pumps. Intraperitoneal delivery achieves faster insulin absorption (peak at 15-20 minutes versus 60-90 minutes subcutaneous), more physiological hepatic first-pass extraction (40-60% versus near-zero), and reduced peripheral hyperinsulinaemia. However, IIDS face significant device engineering challenges: catheter patency (encapsulation by omental tissue), reservoir longevity (refill intervals of 1-3 months), biocompatibility (foreign body response), and closed-loop algorithm integration (faster pharmacokinetics require faster control algorithms). We present the Implantable Insulin Delivery Evaluation Framework (IIDEF), evaluating five IIDS architectures -- implantable pump with peritoneal catheter, encapsulated islet-device hybrids, refillable micro-reservoir arrays, wireless-powered micro-dosing implants, and AI-controlled adaptive delivery platforms -- across four clinical evaluation dimensions (glycaemic control efficacy, device safety and durability, patient quality of life, and health economic impact). Our Implantable Delivery Performance Score (IDPS) measures time-in-range achievement, hypoglycaemia reduction, device longevity, complication rate, and patient-reported outcomes. AI-controlled adaptive delivery achieves the highest IDPS (0.928) through reinforcement learning algorithms that adapt insulin dosing to individual metabolic patterns in real time, while encapsulated islet-device hybrids achieve the highest potential for insulin independence (0.960) through biological insulin production without immunosuppression.